Latest Eszopiclone Stories

How to Help Overcome Insomnia Naturally According to InsomniaMiracleRelief.net New York, NY (PRWEB) March 22, 2013 The United States has now surpassed the 64 million mark of insomnia sufferers. "Women are 1.4 more times likely to get insomnia than men" says Shawn from InsomniaMiracleRelief.net Energy drink consumption is on the rise and the stress of today's society are contributors to the rise in insomnia. Breakthrough drugs like Ambien and Lunesta are alternatives to...

Tokyo, Apr 17, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the insomnia treatment Lunesta(R) (eszopiclone) in Japan on April 18. Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc.; currently a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd.), is the first non-benzodiazepine type GABAA agonist to be launched in Japan in 12 years, and is believed to enhance GABA...

A new study finds that people who take certain commonly prescribed sleeping pills have a five-fold increased risk of death, even among those taking fewer than 18 doses a year. And these drugs are also linked to a significantly increased risk of cancer among those taking high doses, the study, published in the journal BMJ Open, shows. The study, analyzing 10,500 people who took a wide-range of sleeping pills including zolpidem, diazepam and tamazepam, found that the top third of sleeping...

Tokyo, Jan 18, 2012 - (JCN Newswire) - Eisai Co. Ltd announced today that it received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) on January 18, 2012 to market Lunesta (eszopiclone), a product the company has been developing in Japan, as a treatment for insomnia.Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc., "Sepracor"; a U.S. subsidiary of Dainippon Sumitomo Pharma Co....

Adults who take one of the world's most commonly prescribed sleep medications are significantly more at risk for nighttime falls and potential injury, according to a new study by the University of Colorado at Boulder.The study, which involved 25 healthy adults, showed 58 percent of the older adults and 27 percent of the young adults who took a hypnotic, sleep-inducing drug called zolpidem showed a significant loss of balance when awakened two hours after sleep. The findings are important...

When sleep doesn't come easily, some people turn to what they think is an easy solution "“ sleeping pills. But according to a Baylor College of Medicine sleep expert, sleep medications "“ whether prescription or over-the-counter "“ shouldn't be taken lightly."All medications have side effects that need to be weighed whenever you take them," cautioned Dr. Phil Alapat, assistant professor of pulmonary, critical care and sleep medicine at BCM and medical director of the BCM Sleep...

BALTIMORE, March 22 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Eszopiclone tablets, 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration (USFDA). Lupin's Eszopiclone tablets are the AB-rated generic equivalent of Sepracor's LUNESTA® tablets, indicated for the treatment of insomnia. The brand product had annual sales of approximately $761 million for the...

WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for...

Electronic alerts persuade clinicians to switch from costly drugs to generic brandsSimple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs, according to a study in the August issue of Journal of General Internal Medicine. The study found that when clinicians received computerized alerts, which compared medication brands, they changed 23.3 percent of prescriptions for four heavily marketed sleep medications to comparable generic...

U.S. drug labels often omit key information about a medicine's effectiveness and the severity of its side effects, according to a commentary written by two doctors in the New England Journal of Medicine.Such omission of data can result in some medicines appearing safer and more effective than they actually are, wrote Drs. Lisa Schwartz and Steven Woloshin of the Dartmouth Institute for Health Policy and Clinical Practice in Hanover, New Hampshire."The most direct way that the FDA communicates...